Custom-Made vaccine trains immune system to fight advanced cancers

NCT ID NCT05098210

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast cancer, or non-small cell lung cancer that has not responded to prior treatments. The main goal is to check the safety of this approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized neo-antigen peptide vaccine
What this could lead to: If successful, this could point toward a new way to help the immune system recognize and attack advanced cancers that have not responded to other treatments.
What could go wrong: This is a very early phase 1 trial with only 25 participants, so safety and effectiveness are not yet known. The vaccine is custom-made for each person, which is complex and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acral lentiginous melanoma breast cancer cutaneous melanoma Her2-receptor negative breast cancer hormone receptor-positive breast cancer lung cancer lung neoplasm malignant conjunctival melanoma malignant melanoma of the mucosa melanoma metastatic malignant neoplasm metastatic melanoma mucosal melanoma Neoplasm Metastasis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE IV BREAST CANCER AJCC V8 CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 LOCALLY ADVANCED CUTANEOUS MELANOMA LOCALLY ADVANCED MUCOSAL MELANOMA METASTATIC ACRAL MELANOMA METASTATIC CONJUNCTIVAL MELANOMA METASTATIC CUTANEOUS MELANOMA METASTATIC HER2-NEGATIVE BREAST CARCINOMA METASTATIC HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA METASTATIC LUNG NON-SMALL CELL CARCINOMA METASTATIC MALIGNANT SOLID NEOPLASM METASTATIC MUCOSAL MELANOMA PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIID CUTANEOUS MELANOMA AJCC V8 RECURRENT CUTANEOUS MELANOMA RECURRENT HER2-NEGATIVE BREAST CARCINOMA RECURRENT HORMONE RECEPTOR-POSITIVE BREAST CARCINOMA RECURRENT LUNG NON-SMALL CELL CARCINOMA RECURRENT MUCOSAL MELANOMA STAGE III LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8 UNRESECTABLE ACRAL MELANOMA UNRESECTABLE CUTANEOUS MELANOMA UNRESECTABLE LUNG NON-SMALL CELL CARCINOMA UNRESECTABLE MUCOSAL MELANOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.